» Articles » PMID: 32131479

Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances

Overview
Journal Brain Sci
Publisher MDPI
Date 2020 Mar 6
PMID 32131479
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

This survey aimed to explore knowledge and experience on novel psychoactive substances (NPS) of healthcare professionals (HCPs). The study also aimed to assess how HCPs would like to improve their knowledge of NPS. : Seventy paper questionnaires were disseminated in 2017 within continuing education events to pharmacists, nurses and general practitioners (GPs). Additionally, 127 online surveys were completed using the Qualtrics platform by other HCPs and mental health nurses in six United Kingdom (UK) independent mental health hospitals long-stay in-patient rehabilitation services. Two educational sessions involving pharmacists and GPs were also held in late 2017 and mid-2018. Knowledge of NPS by HCPs was evaluated prior to the start of the educational events. Evaluation forms were handed out post-sessions to garner feedback, especially on areas for improvement for future sessions. Statistical analysis of data was undertaken using SPSS (V.25). : Most HCPs reported only 'basic' to 'intermediate' NPS knowledge. Substance misuse service staff felt more informed, were more often consulted and had greater confidence regarding NPS compared to hospital and primary care professionals. A negative association was found between the age of the HCP and knowledge of NPS. Most participants expressed a need for regular training and updates as insufficient NPS-related information is currently received. : An improvement within the self-reported knowledge of HCPs on NPS is evident in comparison to previous studies. Continued education of HCPs on NPS is fundamental for the provision of improved harm reduction services, which can enhance overall care for NPS service users.

Citing Articles

Systematic review: The relationship between gabapentinoids, etizolam, and drug related deaths in Scotland.

Ciesluk B, Inglis D, Parke A, Troup L PLoS One. 2024; 19(10):e0310655.

PMID: 39383139 PMC: 11463789. DOI: 10.1371/journal.pone.0310655.


Identifying and Exploring Jean Watson's Theory of Human Caring in Nursing Approaches for Patients with Psychoactive Substance Dependence in Medical and Surgical Acute Wards.

Curcio F, Lommi M, Bermeo R, Esteban-Burgos A, Pucciarelli G, Gonzalez C Nurs Rep. 2024; 14(3):2179-2191.

PMID: 39311171 PMC: 11417922. DOI: 10.3390/nursrep14030162.


New Psychoactive Substances: Awareness and Attitudes of Future Health Care Professionals in Serbia.

Mijatovic Jovin V, Skoko N, Tomas A, Zivanovic D, Sazdanic D, Gvozdenovic N Int J Environ Res Public Health. 2022; 19(22).

PMID: 36429596 PMC: 9691219. DOI: 10.3390/ijerph192214877.


"Hot" and "Cold" Cognition in Users of Club Drugs/Novel Psychoactive Substances.

Savulich G, Bowden-Jones O, Stephenson R, Bruhl A, Ersche K, Robbins T Front Psychiatry. 2021; 12:660575.

PMID: 33841219 PMC: 8024487. DOI: 10.3389/fpsyt.2021.660575.


Piloting the UK's First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service.

Guirguis A, Gittins R, Schifano F Behav Sci (Basel). 2020; 10(8).

PMID: 32722508 PMC: 7465824. DOI: 10.3390/bs10080121.

References
1.
Goodair C, Corkery J, Claridge H . Legal highs: a problem of definitions?. Lancet. 2014; 383(9930):1715. DOI: 10.1016/S0140-6736(14)60822-9. View

2.
Alotaibi M, Husbands S, Blagbrough I . ¹H, ¹³C, ¹⁵N HMBC, and ¹⁹F NMR spectroscopic characterisation of seized flephedrone, cut with benzocaine. J Pharm Biomed Anal. 2015; 107:535-8. DOI: 10.1016/j.jpba.2014.12.033. View

3.
Schifano F . Recent Changes in Drug Abuse Scenarios: The New/Novel Psychoactive Substances (NPS) Phenomenon. Brain Sci. 2018; 8(12). PMC: 6316773. DOI: 10.3390/brainsci8120221. View

4.
Bersani F, Corazza O, Albano G, Valeriani G, Santacroce R, Bolzan Mariotti Posocco F . 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int. 2014; 2014:734749. PMC: 4106087. DOI: 10.1155/2014/734749. View

5.
Deligianni E, Daniel O, Corkery J, Schifano F, Lione L . Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances. Br J Clin Pharmacol. 2019; 86(3):505-516. PMC: 7080634. DOI: 10.1111/bcp.14123. View